Recombinant T-Cell Receptor Ligand (RTL) for Treatment of Multiple Sclerosis: A Double-Blind, Placebo-Controlled, Phase 1, Dose-Escalation Study

Background. Recombinant T-cell receptor ligand 1000 (RTL1000) is a single-chain protein construct containing the outer two domains of HLA-DR2 linked to myelin-oligodendrocyte-glycoprotein- (MOG-) 35–55 peptide. Analogues of RTL1000 induce T-cell tolerance, reverse clinical and histological disease,...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Yadav, Vijayshree, Bourdette, Dennis N., Bowen, James D., Lynch, Sharon G., Mattson, David, Preiningerova, Jana, Bever, Christopher T., Simon, Jack, Goldstein, Andrew, Burrows, Gregory G., Offner, Halina, Ferro, Al J., Vandenbark, Arthur A.
Format: Artigo
Idioma:Inglês
Publicat: Hindawi Publishing Corporation 2012
Matèries:
Clinical Study
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3328144/
https://ncbi.nlm.nih.gov/pubmed/22548151
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1155/2012/954739
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars